Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol Barnes T; Moots RInt J Nanomedicine 2007[]; 2 (1): 3-7Anti-TNFalpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFalpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFalpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.|Antibodies, Monoclonal, Humanized[MESH]|Antimicrobial Cationic Peptides/*chemistry[MESH]|Antirheumatic Agents/administration & dosage/chemistry[MESH]|Arthritis, Rheumatoid/*drug therapy[MESH]|Certolizumab Pegol[MESH]|Clinical Trials as Topic/*trends[MESH]|Drug Carriers/*chemistry[MESH]|Drug Delivery Systems/*methods[MESH]|Humans[MESH]|Immunoglobulin Fab Fragments/*administration & dosage/*chemistry[MESH]|Nanomedicine/methods/trends[MESH]|Polyethylene Glycols/*administration & dosage/*chemistry[MESH] |